临床肿瘤学杂志
臨床腫瘤學雜誌
림상종류학잡지
CHINESE CLINICAL ONCOLOGY
2014年
3期
216-220
,共5页
黄小银%王建东%孙茜%付海京%管晓翔%王靖华
黃小銀%王建東%孫茜%付海京%管曉翔%王靖華
황소은%왕건동%손천%부해경%관효상%왕정화
弥漫性大B细胞淋巴瘤%免疫组织化学%EphA2%预后
瀰漫性大B細胞淋巴瘤%免疫組織化學%EphA2%預後
미만성대B세포림파류%면역조직화학%EphA2%예후
Diffuse large B-cell lymphoma%Immunohistochemistry%EphA2%Prognosis
目的:探讨EphA2蛋白在弥漫性大B细胞淋巴瘤( DLBCL)中的表达情况及其与临床病理特征和预后的关系。方法采用免疫组化EnVision法检测72例DLBCL及10例正常淋巴结组织中EphA2蛋白的表达情况,分析DLBCL组织中EphA2蛋白表达与性别、年龄、分期、B症状、乳酸脱氢酶( LDH)、国际预后指数( IPI)及病理分型等临床病理特征的关系,随访DLBCL患者的生存情况并分析中位生存期(OS)和无进展生存期(PFS),同时采用Cox多因素分析影响预后的独立因素。结果 DLBCL组织中EphA2蛋白的阳性表达率为58.3%(42/72),高于正常淋巴结组织的20.0%(2/10),差异有统计学意义( P<0.05);EphA2蛋白表达与分期、病理分型有关,而与性别、年龄、B症状、LDH和IPI均无关( P>0.05)。全组的中位PFS和OS分别为15.5和22.0个月, LDH是影响PFS和OS的独立预后因素,IPI仅是影响PFS的独立预后因素,分期、EphA2蛋白表达均是影响OS的独立预后因素( P<0.05)。结论 EphA2蛋白在DLBCL中高表达,其表达与分期、病理分型有关,EphA2阳性表达提示预后不佳。
目的:探討EphA2蛋白在瀰漫性大B細胞淋巴瘤( DLBCL)中的錶達情況及其與臨床病理特徵和預後的關繫。方法採用免疫組化EnVision法檢測72例DLBCL及10例正常淋巴結組織中EphA2蛋白的錶達情況,分析DLBCL組織中EphA2蛋白錶達與性彆、年齡、分期、B癥狀、乳痠脫氫酶( LDH)、國際預後指數( IPI)及病理分型等臨床病理特徵的關繫,隨訪DLBCL患者的生存情況併分析中位生存期(OS)和無進展生存期(PFS),同時採用Cox多因素分析影響預後的獨立因素。結果 DLBCL組織中EphA2蛋白的暘性錶達率為58.3%(42/72),高于正常淋巴結組織的20.0%(2/10),差異有統計學意義( P<0.05);EphA2蛋白錶達與分期、病理分型有關,而與性彆、年齡、B癥狀、LDH和IPI均無關( P>0.05)。全組的中位PFS和OS分彆為15.5和22.0箇月, LDH是影響PFS和OS的獨立預後因素,IPI僅是影響PFS的獨立預後因素,分期、EphA2蛋白錶達均是影響OS的獨立預後因素( P<0.05)。結論 EphA2蛋白在DLBCL中高錶達,其錶達與分期、病理分型有關,EphA2暘性錶達提示預後不佳。
목적:탐토EphA2단백재미만성대B세포림파류( DLBCL)중적표체정황급기여림상병리특정화예후적관계。방법채용면역조화EnVision법검측72례DLBCL급10례정상림파결조직중EphA2단백적표체정황,분석DLBCL조직중EphA2단백표체여성별、년령、분기、B증상、유산탈경매( LDH)、국제예후지수( IPI)급병리분형등림상병리특정적관계,수방DLBCL환자적생존정황병분석중위생존기(OS)화무진전생존기(PFS),동시채용Cox다인소분석영향예후적독립인소。결과 DLBCL조직중EphA2단백적양성표체솔위58.3%(42/72),고우정상림파결조직적20.0%(2/10),차이유통계학의의( P<0.05);EphA2단백표체여분기、병리분형유관,이여성별、년령、B증상、LDH화IPI균무관( P>0.05)。전조적중위PFS화OS분별위15.5화22.0개월, LDH시영향PFS화OS적독립예후인소,IPI부시영향PFS적독립예후인소,분기、EphA2단백표체균시영향OS적독립예후인소( P<0.05)。결론 EphA2단백재DLBCL중고표체,기표체여분기、병리분형유관,EphA2양성표체제시예후불가。
Objective To investigate the clinical and prognostic significance of EphA2 expression in diffuse large B-cell lym-phoma(DLBCL). Methods The immunohistochemistry(EnVision method)was applied to detect the protein expression of EphA2 on tissue sections from 72 DLBCL and 10 normal lymph tissues. Then the relationships between EphA2 expression and clinicopathological variables including gender, age, stage, B symptoms, lactate dehydrogenase( LDH) , international prognostic index( IPI) and patholog-ical type were analyzed. The DLBCL patients were followed up for medium progression-free survival(PFS)and overall survival(OS). Multivariate analysis of these prognostic factors was then performed using the Cox proportional hazards. Results Positive expression rate of EphA2 was 58.3%( 42/72) in DLBCL tissues, higher than 20.0%( 2/10) of normal lymph tissues( P<0.05) . EphA2 expression was related with staging and pathological type, but not with sex, age, B symptoms, LDH and IPI( P>0.05) . The median PFS and OS of 72 DLBCL patients were 15.5 and 22.0 months. LDH was an independent prognostic factor for PFS and OS. IPI only was the inde-pendent prognostic factor for PFS, while staging and EphA2 protein expression were independent prognostic factors for OS( P<0.05) . Conclusion There was a high expression rate of EphA2 protein in DLBCL, and its expression was related with staging and pathologi-cal type. The positive expression of EphA2 indicated a poor prognosis for DLBCL.